CIDM vs. BTX, ALFIW, and NLOK
Should you be buying Cinedigm stock or one of its competitors? The main competitors of Cinedigm include Brooklyn ImmunoTherapeutics (BTX), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.
Cinedigm (NASDAQ:CIDM) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both small-cap information companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.
Cinedigm and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users.
8.0% of Cinedigm shares are owned by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 16.4% of Cinedigm shares are owned by insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Cinedigm has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, suggesting that its share price is 361% more volatile than the S&P 500.
In the previous week, Brooklyn ImmunoTherapeutics had 1 more articles in the media than Cinedigm. MarketBeat recorded 1 mentions for Brooklyn ImmunoTherapeutics and 0 mentions for Cinedigm. Cinedigm's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score.
Brooklyn ImmunoTherapeutics has lower revenue, but higher earnings than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Brooklyn ImmunoTherapeutics beats Cinedigm on 5 of the 7 factors compared between the two stocks.
Get Cinedigm News Delivered to You Automatically
Sign up to receive the latest news and ratings for CIDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CIDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cinedigm Competitors List
Related Companies and Tools
